

Creative Biolabs: Leading the Way to the Future of Immunotherapy Research with Precision and Innovation

Creative Biolabs is leading the way to the future of immunotherapy research with innovative tools that enable researchers to explore new ways.

SHIRLEY, NY, UNITED STATES, June 24, 2025 /EINPresswire.com/ -- With increasingly advanced research, the convergence of genetic biomarkers, stem cell biology, and macrophage engineering increasingly enhances experimental models and analytic methods, such that immunotherapy is at the forefront of cutting-edge biomedical science. The research investigators are able to use the specialty reagents and solutions offered by Creative Biolabs to explore key immune mechanisms, such as iPSC-derived services, complement activity assays, and high-quality [macrophage cell lines](#). These advances pave the way for better therapeutic design.

There are many array kits for the study of the complement system. These tools enable the identification of new targets and receptors in various diseases using the exploitation of the heterogeneous proteins of the complement pathway.

For instance, Creative Biolabs' [CH50 functional assay kit](#) is able to measure the activity of the classical complement pathway in terms of an erythrocyte hemolysis assay. The functional assay is also capable of screening and evaluating the pharmacological action of complement-targeting inhibitors or activators.

Fibroblast growth factor 2 ([FGF2](#)) is one of the most critical components of iPSC culture medium and plays an important role in maintaining iPSC pluripotency and self-renewal. Creative Biolabs offers two best-performance FGF2 products: a recombinant human FGF2 with greater stability for longer efficacy and a more stabilized version of FGF2 with higher bioactivity to support strong proliferation. Both undergo rigorous quality control to deliver perfect iPSC culture conditions.

"Here at Creative Biolabs, we've invested in developing innovative research tools to drive the science ahead, and it's been rewarding," said the manager. "We're excited to share our latest advancements at the 5th Oligonucleotides for CNS Summit. We're anticipating meeting researchers, learning from one another, and defining the future of immunotherapy."

Creative Biolabs collaborates with academies of research, biotechnology firms, and pharmaceutical firms in providing tailored project development services, assay design, and

therapeutic pipeline optimization. Through AI-researched technology and data analysis, the firm aims to achieve optimum drug discovery efficiency.

For more details about immunotherapy solutions, please visit <https://www.creative-biolabs.com/complement-therapeutics/>.

About Creative Biolabs

Creative Biolabs remains dedicated to offering innovative solutions that make the lives of research professionals and drug developers easier. From high-throughput screening technology to custom immunotherapy design, the company enables leading scientists to find the latest resources available in the industry.

Candy Swift

Creative Biolabs

+ +1 631-830-6441

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/825047749>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.